Sellas Life Sciences

Yahoo Finance • 16 days ago

Vishay Intertechnology, Eos Energy Enterprises, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday

U.S. stocks were mixed, with the Nasdaq Composite gaining more than 100 points on Wednesday. Shares of Vishay Intertechnology Inc(NYSE:VSH) rose sharply after the company reported better-than-expected first-quarter financial results and i... Full story

Yahoo Finance • 17 days ago

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers Quantum Cyber (NASDAQ:QUCY) shares increased by 55.0% to $0.5 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.0 million. SELLAS Life Sciences Gr (NASDAQ:SLS) shares increased by 21.26%... Full story

Yahoo Finance • 17 days ago

Why Nextpower Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket

Shares of Nextpower Inc(NASDAQ:NXT) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results and raised its FY27 sales guidance. The company announced it will acquire assets of Zig... Full story

Yahoo Finance • last month

SELLAS Life Sciences Group Inc. (SLS) Making Progress on Key Acute Myeloid Leukemia Treatment

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the best healthcare penny stocks to buy according to hedge funds. On March 19, Chief Executive Officer Angelos Stergiou reiterated that 2026 is poised to be a pivotal year for Sellas L... Full story

Yahoo Finance • 2 months ago

These 16 stocks are a short seller’s dream — likely losers no matter what the market does

- Getty Images/iStockphoto Certain stocks are good bets to lag the market in the coming months, according to a new study, regardless of what the market does. Sixteen of these stocks are listed in a table at the end of this column. Short... Full story

Yahoo Finance • 2 months ago

SELLAS FY25 Net Loss Narrows; Approaching Final Analysis Of The Phase 3 REGAL Trial For GPS In AML

(RTTNews) - SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company, reported financial results for the full year 2025, reflecting a narrower net loss and provided a clinical pipeline update. For 2025, net... Full story

Yahoo Finance • 2 months ago

SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of... Full story

Yahoo Finance • 5 months ago

Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge

VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity InsiderNews Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034[1], driven by a fundamental shift in how physi... Full story

Yahoo Finance • 6 months ago

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025

SLS009 in combination with AZA/VEN achieved a 46% overall response rate across all cohorts, a 58% overall response rate in patients with one prior line of therapy, and encouraging survival outcomes in heavily-pretreated AML-MR following pr... Full story

Yahoo Finance • 7 months ago

After-Hours Gainers: MGNX, SLS, KRMD, HYPR, WVE Post Sharp Moves Following Q3 Updates

(RTTNews) - Several small-cap healthcare and biotech names posted notable price increases in after-hours trading on Wednesday, following earnings updates or ahead of scheduled financial disclosures. MacroGenics, Inc. (MGNX) rose 10.2% to... Full story

Yahoo Finance • 7 months ago

Sellas Life Sciences Group Inc. (SLS) Advances Cancer Pipeline with $31M Funding and Upcoming R&D Showcase

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the top long-term biotechnology stocks to buy. On October 27, SELLAS Life Sciences (NASDAQ:SLS) announced the immediate exercise of warrants for 22.4 million shares. The company raised... Full story

Yahoo Finance • 7 months ago

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of ca... Full story

Yahoo Finance • 8 months ago

Sellas Life Sciences files to sell 19.69M shares of common stock for holders

* Sellas Life Sciences (SLS [https://seekingalpha.com/symbol/SLS]) has filed to sell 19,685,040 shares of common stock for holders. * This prospectus is not an offer to sell these securities. * Filing [https://seekingalpha.com/filing... Full story

Yahoo Finance • 9 months ago

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of c... Full story

Yahoo Finance • 9 months ago

Solaris Strengthens Community Partnerships and Advances Key Milestones at Warintza Project

HIGHLIGHTS: Landmark agreement signed with PSHA, completing formal partnerships with all Indigenous organisations surrounding the Warintza Project Pre-Feasibility Study advancing with positive momentum, incorporating updated Mineral Resou... Full story

Yahoo Finance • 9 months ago

How To YieldBoost Brightstar Lottery To 16.3% Using Options

Shareholders of Brightstar Lottery PLC (Symbol: BRSL) looking to boost their income beyond the stock's 4.9% annualized dividend yield can sell the June 2026 covered call at the $17 strike and collect the premium based on the $1.50 bid, whi... Full story

Yahoo Finance • 10 months ago

SELLAS Life Sciences Group Inc (NASDAQ:SLS) Reports Q2 2025 Earnings: Narrower Loss and Clinical Progress Amid Revenue Challenges

SELLAS Life Sciences Group Inc (NASDAQ:SLS [https://www.chartmill.com/stock/quote/SLS]) reported its second-quarter 2025 financial results, with earnings per share (EPS) of -$0.07, slightly better than the analyst consensus estimate of -$0... Full story

Yahoo Finance • 10 months ago

SELLAS Life Sciences Gets Positive IDMC Nod To Continue Phase 3 Trial Of AML Treatment

(RTTNews) - SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, Thursday announced that the Independent Data Monitor... Full story

Yahoo Finance • 10 months ago

IDMC recommends continuation of Phase 3 AML trial for galinpepimut-S

NEW YORK - SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), a clinical-stage biotech company with a market capitalization of $159 million, announced Thursday that the Independent Data Monitoring Committee (IDMC) has recommended continuing th... Full story

Yahoo Finance • 10 months ago

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

-        Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceu... Full story